Overview

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)

Status:
Active, not recruiting

Trial end date:
2021-11-26

Target enrollment:

Participant gender:

Summary

The main reason for this study is to compare the study drug tirzepatide to insulin glargine in participants with type 2 diabetes on metformin with or without a sulfonylurea.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Insulin
Insulin Glargine
Insulin, Globin Zinc
Metformin
Tirzepatide